share_log

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $15

Benzinga Real-time News ·  Aug 18, 2022 06:40

HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $7 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment